Safety Reading Notes

Read safety context beside the research guide.

The CBG and target/pharmacology source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 39598860

PubMed For Dummies Article

CBG and target/pharmacology Evidence Review: the long-form source walk-through

Quick read
  • CBG and target/pharmacology currently has 21 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 39598860
  • The evidence classes most visible in the row language are insufficient (13), and mechanistic or pharmacological (8). PMID 21749363
  • The study-design language most visible in the row language is Narrative or expert review (8), Animal study (7), Cellular or in vitro study (2), and other mapped categories (4). PMID 33998900
  • The repeated topics are receptor, target, metabolic, or pharmacology mechanisms (21), which tells the reader where to start opening PubMed and DOI links. PMID 38885660

Start with the research question

CBG and target/pharmacology is built from 21 source-backed evidence row(s) and 21 research source(s). The current evidence classes read as insufficient (13), and mechanistic or pharmacological (8), and the study-design language most often reads as Narrative or expert review (8), Animal study (7), Cellular or in vitro study (2), and other mapped categories (4). PMID 39598860

The row-level question is not simply whether CBG and target/pharmacology is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are receptor, target, metabolic, or pharmacology mechanisms (21). PMID 25269802

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 33168643

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 40967679

Mechanistic evidence 8 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 28120231

Limits and uncertainty 13 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 25269802

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 42105814

Where this page has the most source density

The largest bucket surfaced for this page is receptor, target, metabolic, or pharmacology mechanisms: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is receptor, target, metabolic, or pharmacology mechanisms: mechanistic or pharmacological, which gives readers another way to see what the literature repeatedly circles. PMID 39598860

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 25269802

Bucket chapters: what the literature is circling

receptor, target, metabolic, or pharmacology mechanisms: insufficient

13 research sources 13 rows (563-582) Evidence class: insufficient

This bucket summarizes source-backed rows focused on receptor, target, metabolic, or pharmacology mechanisms: insufficient. It currently draws from 13 research source(s), so the exact study type matters. PMID 39598860

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 39598860

  • Evidence row 563

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: rece... PMID 39598860

  • Evidence row 582

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: receptor, target, metabolic,... PMID 35615681

receptor, target, metabolic, or pharmacology mechanisms: mechanistic or pharmacological

8 research sources 8 rows (570-583) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on receptor, target, metabolic, or pharmacology mechanisms: mechanistic or pharmacological. It currently draws from 8 research source(s), so the exact study type matters. PMID 25269802

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 25269802

  • Evidence row 570

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target,... PMID 25269802

  • Evidence row 583

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target,... PMID 41435878

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (8 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 39598860

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 25269802

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 40540228
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 40326034
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 39003387

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 39598860

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 25269802

Source-reading checklist for CBG and target/pharmacology

  1. Open the linked PubMed or DOI record. PMID 35887277
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 22150623
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 40046175
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 37305529
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 41155621

Source Notes

CBG and target/pharmacology source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 563

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 39598860

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.
  2. Evidence row 564

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21749363

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
  3. Evidence row 565

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 33998900

    Evidence class: insufficient; Study design: Systematic review. Source: The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies.
  4. Evidence row 566

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 38885660

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion.
  5. Evidence row 567

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 33168643

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacological Case for Cannabigerol.
  6. Evidence row 568

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40967679

    Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
  7. Evidence row 569

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28120231

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Pharmacology of Phytocannabinoids.
  8. Evidence row 570

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 25269802

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.
  9. Evidence row 571

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 42105814

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.
  10. Evidence row 572

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40540228

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities.
  11. Evidence row 573

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40326034

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis.
  12. Evidence row 574

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 39003387

    Evidence class: insufficient; Study design: Human clinical study. Source: Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial.
  13. Evidence row 575

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 35887277

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Origin and Biomedical Relevance of Cannabigerol.
  14. Evidence row 576

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 22150623

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid hyperemesis syndrome.
  15. Evidence row 577

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40046175

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacology of Cannabinoids in Chronic Pain.
  16. Evidence row 578

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 37305529

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat.
  17. Evidence row 579

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 41155621

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerol Modulates Cannabinoid Receptor Type 2 Expression in the Spinal Dorsal Horn and Attenuates Neuropathic Pain Models.
  18. Evidence row 580

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40706771

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation.
  19. Evidence row 581

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 20002104

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist.
  20. Evidence row 582

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 35615681

    Evidence class: insufficient; Study design: Human clinical study. Source: Acute Cannabigerol Administration Lowers Blood Pressure in Mice.
  21. Evidence row 583

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 41435878

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerol reverses mechanical allodynia through α2A-adrenergic modulation of thalamocortical signaling in chemotherapy-induced neuropathy.